TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo? MDMA and novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has been contracted as a supplier of MDMA to a clinical trial at Johns Hopkins Medicine.

“We’re looking forward to continuing to provide exceptional service – as well as robust investigational drug product – to researchers in the US and around the world,” said Nicholas Kadysh, CEO, PharmAla Biotech. “Over the past month we have been in communication with a great number of researchers, and we believe that only PharmAla is in a position to fulfill the need for GMP MDMA that has met the quality standards set by regulators like FDA.”

Researchers can access a new tool, offered at https://pharmala.ca/clinical-trials, which provides access to drug product quality information, which researchers can examine directly. PharmAla is confident that it can offer research customers rapid support to convert their clinical trial registrations and IRB approvals to the LaNeo MDMA Chemistry, Manufacturing and Control package.

Conclusion of Contract with Red Light Holland

PharmAla is disclosing that the Company initiated procedures to terminate its agreement with Red Light Holland, and that said contract was concluded on September 3, 2024.

Presentation at European Behavioural Pharmacology Society (“EBPS”) Workshop

PharmAla is furthermore pleased to have been selected to present the data on its novel proprietary molecule, APA-01, as “Hot Topics” at the EBPS Workshop on September 26th. The presentation "APA-01 : Development of a potent entactogen with improved safety pharmacology compared to MDMA" discusses results of PharmAla’s pre-clinical animal research.

“We are delighted with our acceptance for Hot Topics, a testament to the work we continue to do in identifying and validating novel MDMA-like molecules with improved safety pharmacology,” said Dr. Harpreet Kaur, Vice President of Research at PharmAla Biotech. “We are pleased that our work with the Fantegrossi lab has continued to be noted and considered highly by academic researchers and are looking forward to presenting some of our results.”

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla’s research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.